The superior antitumor response following HER2-DC1 i.t. in combination with anti-HER2 antibodies involves tumor infiltration of CD4+ and CD8+ T cells, B cells, NKT cells and NK cells. The gene discussed is ERBB2; the disease is neoplasm.